The route of inoculation determines the tissue tropism of modified vaccinia tiantan expressing the spike glycoprotein of SARS-CoV in mice

Journal of Medical Virology

Volumn 82, Issue 5, 2010, Pages 727-734

  Liu, Huan ^a   Yu, Wenbo ^b   Tang, Xian ^b   Wang, Haibo ^b   Ouyang, Wenjie ^a   Zhou, Jingying ^b   Chen, Zhiwei ^b  

^a WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

MVTT; Tissue tropism; Vaccination route; Vaccine; Vaccinia

Indexed keywords

PLACEBO; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CERVICAL LYMPH NODE; CONTROLLED STUDY; DNA SEQUENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INGUINAL LYMPH NODE; INJECTION; KIDNEY; LUNG; MODIFED VACCINIA VIRUS TIANTAN; MOUSE; NONHUMAN; OVARY; REAL TIME POLYMERASE CHAIN REACTION; SARS CORONAVIRUS; SPLEEN; UTERUS; VACCINATION; VACCINIA VIRUS; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; ANIMAL STRUCTURES; ANIMALS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INJECTIONS, INTRAMUSCULAR; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; SARS VIRUS; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL TROPISM; VIRAL VACCINES;

MUS; SARS CORONAVIRUS; VACCINIA VIRUS;

EID: 77951017160     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21667     Document Type: Article

References (40)

1. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101:6641-6646. (Pubitemid 38586027)
2. Brenchley JM, Douek DC. 2008. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 3:356-361. (Pubitemid 351521021)
3. Broliden K, Haase AT, Ahuja SK, Shearer GM, Andersson J. 2009. Introduction: Back to basics: Mucosal immunity and novel HIV vaccine concepts. J Intern Med 265:5-17.
4. Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 71:3031-3038. (Pubitemid 27119947)
5. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. 2005. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79:2678-2688.
6. Davis NL, Brown KW, Johnston RE. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol 70:3781-3787.
7. de Waal L, Wyatt LS, Yuksel S, van Amerongen G, Moss B, Niesters HG, Osterhaus AD, de Swart RL. 2004. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 22:923-926.
8. Degano P, Schneider J, Hannan CM, Gilbert SC, Hill AV. 1999. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD8+T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18:623-632. (Pubitemid 29509846)
9. Demberg T, Robert-Guroff M. 2009. Mucosal immunity and protection against HIV/SIV infection: Strategies and challenges for vaccine design. Int Rev Immunol 28:20-48.
10. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. 1999. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol 162:1603-1610.
11. Forrest BD. 1992. Mucosal approaches to HIV vaccine development. AIDS Res Hum Retroviruses 8:1523-1525.
12. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. 2004. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: Enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 172:6209-6220. (Pubitemid 38621227)
13. Girard MP, Bansal GP, Pedroza-Martins L, Dodet B, Mehra V, Schito M, Mathieson B, Delfraissy JF, Bradac J. 2008. Mucosal immunity and HIV/AIDS vaccines. Report of an International Workshop, 28-30 October2007. Vaccine 26:3969-3977.
14. Haynes BF, Shattock RJ. 2008. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 122:3-9 quiz 10-11.
15. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat Med 11:S45-S53.
16. Huang X, Lu B, Yu W, Fang Q, Liu L, Zhuang K, Shen T, Wang H, Tian P, Zhang L, Chen Z. 2009. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoSONE 4:e4180.
17. Kastenmuller W, Gasteiger G, Stross L, Busch DH, Drexler I. 2009. Cutting edge: Mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity toward intracellular pathogens. J Immunol 182:2573-2577.
18. Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Wilson KM, Ramsay AJ. 2005. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 23:5009-5021.
19. Lehner T, Hussain L, Wilson J, Chapman M. 1991. Mucosal transmission of HIV. Nature 353:709.
20. Mestecky J. 2005. Mucosal immunology 3rd edition. San Diego: Academic Press.
21. Miller CJ, McGhee JR, Gardner MB. 1993. Mucosal immunity, HIV transmission, and AIDS. Lab Invest 68:129-145.
22. Moldoveanu Z, Mestecky J. 2009. Mucosal antibody responses to HIV. Methods Mol Biol 485:333-345.
23. O'Hagan DT. 1991. HIV and mucosal immunity. Lancet 337:1289.
24. Olszewska W, Suezer Y, Sutter G, Openshaw PJ. 2004. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23:215-2221.
25. Osorio JE, Frank RS, Moss K, Taraska T, Powell T, Stinchcomb DT. 2003. Raccoon poxvirus as a mucosal vaccine vector for domestic cats. J Drug Target 11:463-470. (Pubitemid 38519155)
26. Pascual DW, White MD, Larson T, Walters N. 2001. Impaired mucosal immunity in L-selectin-deficient mice orally immunized with a Salmonella vaccine vector. J Immunol 167:407-415. (Pubitemid 32567806)
27. Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H. 2003. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 148:827-839. (Pubitemid 36567936)
28. Schlereth B, Buonocore L, Tietz A, Meulen Vt V, Rose JK, Niewiesk S. 2003. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol 84:2145-2151. (Pubitemid 36927245)
29. Sertl K, Takemura T, Tschachler E, Ferrans VJ, Kaliner MA, Shevach EM. 1986. Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura. J Exp Med 163:436-451. (Pubitemid 16113078)
30. Shacklett BL. 2008. Mucosal immunity to HIV: A review of recent literature. Curr Opin HIV AIDS 3:541-547.
31. Shata MT, Reitz MS, Jr, DeVico AL, Lewis GK, Hone DM. 2001. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20:623-629.
32. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J. 2008. Improving defences at the portal of HIV entry: Mucosal and innate immunity. PLoS Med 5:e81.
33. Stevenson A, Roberts M. 2002. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine 20:2325-2335. (Pubitemid 34497043)
34. Stolte-Leeb N, Bieler K, Kostler J, Heeney J, Haaft PT, Suh YS, Hunsmann G, Stahl-Hennig C, Wagner R. 2008. Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone. Viral Immunol 21:235-246.
35. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040. (Pubitemid 24246876)
36. Wang SW, Bertley FM, Kozlowski PA, Herrmann L, Manson K, Mazzara G, Piatak M, Johnson RP, Carville A, Mansfield K, Aldovini A. 2004. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 20:846-859.
37. WuL. 2008. Biology of HIV mucosal transmission. Curr Opin HIV AIDS 3:534-540.
38. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. 1999. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18:392-397. (Pubitemid 29462594)
39. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. 2009. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 16:367-375.
40. Zhu W, Fang Q, Zhuang K, Wang H, Yu W, Zhou J, Liu L, Tien P, Zhang L, Chen Z. 2007. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J Virol Methods 144:17-26.